01 enero 2015

JACC. Hybrid Coronary Revascularization. Promising, But Yet to Take Off

Vasileios F. Panoulas, MD, PhD∗; Antonio Colombo, MD∗; Alberto Margonato, MD∗; Francesco Maisano, MD§

Abstract: Hybrid coronary revascularization (HCR) combines arterial coronary artery bypass surgery (most commonly minimally invasive) and percutaneous coronary intervention in the treatment of a particular subset of multivessel coronary artery disease. It was first introduced in the mid-1990s, and aspired to bring together the “best of both worlds”: the excellent patency rates and survival benefits associated with the durable left internal mammary artery graft to the left anterior descending artery alongside the good patency rates of drug-eluting stents, which outlive saphenous vein grafts to non–left anterior descending vessels. Although in theory this is a very attractive revascularization strategy, several years later, only one small randomized controlled trial comparing HCR with coronary artery bypass grafting has recently emerged in the medical literature, raising concerns regarding HCR’s role and generalizability. In the current review, we discuss HCR’s rationale, the current evidence behind it, its limitations and procedural challenges.

01 diciembre 2014

JACC. Coronary Artery Bypass Graft Surgery Versus Drug-Eluting Stents for Patients With Isolated Proximal Left Anterior Descending Disease

Edward L. Hannan, PhD∗; Ye Zhong, MD∗; Gary Walford, MD†; David R. Holmes, MD‡; Ferdinand J. Venditti, MD§; Peter B. Berger, MD‖; Alice K. Jacobs, MD¶; Nicholas J. Stamato, MD#; Jeptha P. Curtis, MD∗∗; Samin Sharma, MD††; Spencer B. King, MD‡‡

Background: Few recent studies have compared the outcomes of coronary artery bypass graft (CABG) surgery with percutaneous coronary interventions (PCIs) in patients with isolated (single vessel) proximal left anterior descending (PLAD) coronary artery disease in the era of drug-eluting stents (DES).

01 febrero 2015

JACC. A Randomized Trial of a Dedicated Bifurcation Stent Versus Provisional Stenting in the Treatment of Coronary Bifurcation Lesions

Philippe Généreux, MD∗; Indulis Kumsars, MD§; Maciej Lesiak, MD‖; Annapoorna Kini, MD¶; Géza Fontos, MD#; Ton Slagboom, MD∗∗; Imre Ungi, MD, PhD††; D. Christopher Metzger, MD‡‡; Joanna J. Wykrzykowska, MD, PhD§§; Pieter R. Stella, MD, PhD‖‖; Antonio L. Bartorelli, MD¶¶; William F. Fearon, MD##; Thierry Lefèvre, MD∗∗∗; Robert L. Feldman, MD†††; Laura LaSalle, MPH†; Dominic P. Francese, MPH†; Yoshinobu Onuma, MD, PhD‡‡‡; Maik J. Grundeken, MD§§; Hector M. Garcia-Garcia, MD, PhD‡‡‡; Linda L. Laak, BSN§§§; Donald E. Cutlip, MD‖‖‖; Aaron V. Kaplan, MD§§§; Patrick W. Serruys, MD, PhD‡‡‡; Martin B. Leon, MD∗

Background: Bifurcation lesions are frequent among patients with symptomatic coronary disease treated by percutaneous coronary intervention. Current evidence recommends a conservative (provisional) approach when treating the side branch (SB).

01 febrero 2015

JACC. Systemic Vascular Load in Calcific Degenerative Aortic Valve Stenosis. Insight From Percutaneous Valve Replacement

Raquel Yotti, MD, PhD∗; Javier Bermejo, MD, PhD∗; Enrique Gutiérrez-Ibañes, MD∗; Candelas Pérez del Villar, MD∗; Teresa Mombiela, MD∗; Jaime Elízaga, MD, PhD∗; Yolanda Benito, DCS, DVM∗; Ana González-Mansilla, MD, PhD∗; Alicia Barrio, DCS, MBiol∗; Daniel Rodríguez-Pérez, PhD†; Pablo Martínez-Legazpi, MEng, PhD‡; Francisco Fernández-Avilés, MD, PhD∗

Background: Systemic arterial load impacts the symptomatic status and outcome of patients with calcific degenerative aortic stenosis (AS). However, assessing vascular properties is challenging because the arterial tree’s behavior could be influenced by the valvular obstruction.

01 febrero 2015

JACC. Late Cardiac Death in Patients Undergoing Transcatheter Aortic Valve Replacement. Incidence and Predictors of Advanced Heart Failure and Sudden Cardiac Death

Marina Urena, MD∗; John G. Webb, MD†; Helene Eltchaninoff, MD‡; Antonio J. Muñoz-García, MD, PhD§; Claire Bouleti, MD, PhD‖; Corrado Tamburino, MD¶; Luis Nombela-Franco, MD#; Fabian Nietlispach, MD, PhD∗∗; Cesar Moris, MD††; Marc Ruel, MD‡‡; Antonio E. Dager, MD§§; Vicenç Serra, MD‖‖; Asim N. Cheema, MD¶¶; Ignacio J. Amat-Santos, MD##; Fabio Sandoli de Brito, MD∗∗∗; Pedro Alves Lemos, MD†††; Alexandre Abizaid, MD‡‡‡; Rogério Sarmento-Leite, MD§§§; Henrique B. Ribeiro, MD∗; Eric Dumont, MD∗; Marco Barbanti, MD†; Eric Durand, MD‡; Juan H. Alonso Briales, MD§; Dominique Himbert, MD‖; Alec Vahanian, MD‖; Sebastien Immè, MD¶; Eulogio Garcia, MD#; Francesco Maisano, MD∗∗; Raquel del Valle, MD††; Luis Miguel Benitez, MD§§; Bruno García del Blanco, MD‖‖; Hipólito Gutiérrez, MD##; Marco Antonio Perin, MD∗∗∗; Dimytri Siqueira, MD‡‡‡; Guilherme Bernardi, MD§§§; François Philippon, MD∗; Josep Rodés-Cabau, MD∗

Background: Little evidence exists of the burden and predictors of cardiac death after transcatheter aortic valve replacement (TAVR).

01 febrero 2015

JACC. Mitral Valve Area During Exercise After Restrictive Mitral Valve Annuloplasty. Importance of Diastolic Anterior Leaflet Tethering

Philippe B. Bertrand, MD, MSc∗; Frederik H. Verbrugge, MD∗; David Verhaert, MD∗; Christophe J.P. Smeets, MSc†; Lars Grieten, PhD, MSc∗; Wilfried Mullens, MD, PhD∗; Herbert Gutermann, MD‡; Robert A. Dion, MD, PhD‡; Robert A. Levine, MD§; Pieter M. Vandervoort, MD∗

Background: Restrictive mitral valve annuloplasty (RMA) for secondary mitral regurgitation might cause functional mitral stenosis, yet its clinical impact and underlying pathophysiological mechanisms remain debated.

01 febrero 2015

JACC. Myocardial Edema After Ischemia/Reperfusion Is Not Stable and Follows a Bimodal Pattern. Imaging and Histological Tissue Characterization

Rodrigo Fernández-Jiménez, MD∗; Javier Sánchez-González, PhD∗; Jaume Agüero, MD∗; Jaime García-Prieto, BSc∗; Gonzalo J. López-Martín, Tech∗; José M. García-Ruiz, MD∗; Antonio Molina-Iracheta, DVM∗; Xavier Rosselló, MD∗; Leticia Fernández-Friera, MD, PhD∗; Gonzalo Pizarro, MD∗; Ana García-Álvarez, MD, PhD∗; Erica Dall´Armellina, MD, DPhil¶; Carlos Macaya, MD, PhD†; Robin P. Choudhury, DM¶; Valentin Fuster, MD, PhD∗; Borja Ibáñez, MD, PhD∗

Background: It is widely accepted that edema occurs early in the ischemic zone and persists in stable form for at least 1 week after myocardial ischemia/reperfusion. However, there are no longitudinal studies covering from very early (minutes) to late (1 week) reperfusion stages confirming this phenomenon.

01 marzo 2015

JACC. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin. The Randomized, Multicenter ITALIC Trial

Martine Gilard, MD, PhD∗; Paul Barragan, MD†; Arif A.L. Noryani, MD‡; Hussam A. Noor, MD§; Talib Majwal, MD‖; Thomas Hovasse, MD¶; Philippe Castellant, MD∗; Michel Schneeberger, MD#; Luc Maillard, MD, PhD∗∗; Erwan Bressolette, MD††; Jaroslaw Wojcik, MD‡‡; Nicolas Delarche, MD§§; Didier Blanchard, MD‖‖; Bernard Jouve, MD¶¶; Olivier Ormezzano, MD##; Franck Paganelli, MD∗∗∗; Gilles Levy, MD†††; Joël Sainsous, MD‡‡‡; Didier Carrie, MD§§§; Alain Furber, MD, PhD‖‖‖; Jacques Berland, MD¶¶¶; Oliver Darremont, MD###; Hervé Le Breton, MD∗∗∗∗; Anne Lyuycx-Bore, MD††††; Antoine Gommeaux, MD‡‡‡‡; Claude Cassat, MD§§§§; Alain Kermarrec, MD‖‖‖‖; Pierre Cazaux, MD¶¶¶¶; Philippe Druelles, MD####; Raphael Dauphin, MD∗∗∗∗∗; Jean Armengaud, MD†††††; Patrick Dupouy, MD‡‡‡‡‡; Didier Champagnac, MD§§§§§; Patrick Ohlmann, MD‖‖‖‖‖; Knut Endresen, MD¶¶¶¶¶; Hakim Benamer, MD#####; Robert Gabor Kiss, MD∗∗∗∗∗∗; Imre Ungi, MD††††††; Jacques Boschat, MD∗; Marie-Claude Morice, MD¶

Background: The currently recommended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent (DES) recipients is 12 months to reduce the risk of late stent thrombosis, particularly in those with acute coronary syndrome (ACS).

01 marzo 2015

JACC. Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds

Serban Puricel, MD; Diego Arroyo, MD; Noé Corpataux, BSc; Gérard Baeriswyl, MD; Sonja Lehmann, BSc; Zacharenia Kallinikou, MD; Olivier Muller, MD; Ludovic Allard, MD; Jean-Christophe Stauffer, MD; Mario Togni, MD; Jean-Jacques Goy, MD; Stéphane Cook, MD

Background: The first CE-approved bioresorbable vascular scaffold (BVS) is effective at treating simple lesions and stable coronary artery disease, but it has yet to be assessed versus the best-in-class drug-eluting stents (DES).

01 marzo 2015

JACC. Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates

Marco Valgimigli, MD, PhD∗; Athanasios Patialiakas, MD†; Attila Thury, MD, PhD§; Eugene McFadden, MD‖; Salvatore Colangelo, MD¶; Gianluca Campo, MD†; Matteo Tebaldi, MD†; Imre Ungi, MD, PhD§; Stefano Tondi, MD#; Marco Roffi, MD∗∗; Alberto Menozzi, MD, PhD††; Nicoletta de Cesare, MD‡‡; Roberto Garbo, MD¶; Emanuele Meliga, MD§§; Luca Testa, MD, PhD‖‖; Henrique Mesquita Gabriel, MD¶¶; Flavio Airoldi, MD##; Marco Ferlini, MD∗∗∗; Francesco Liistro, MD†††; Antonio Dellavalle, MD‡‡‡; Pascal Vranckx, MD, PhD§§§; Carlo Briguori, MD, PhD‖‖‖

Background: The use of drug-eluting stents (DES) in patients at high risk of bleeding or thrombosis has not been prospectively studied; limited data are available in patients who have a low restenosis risk.

05 noviembre 2014

CIRCULATION. Cardiovascular Surgery. Endovascular Treatment of Mycotic Aortic Aneurysms

Karl Sörelius, MD; Kevin Mani, MD, PhD; Martin Björck, MD, PhD; Petr Sedivy, MD, PhD; Carl-Magnus Wahlgren, MD, PhD; Peter Taylor, MA, MChir, FRCS; Rachel E. Clough, PhD, MRCS; Oliver Lyons, MRCS, PhD; Matt Thompson, MD, FRCS; Jack Brownrigg, MBChB, MRCS; Krassi Ivancev, MD, PhD; Meryl Davis, BSc, MBBS, FRCS; Michael P. Jenkins, BSc, MBBS, MS, FRCS, FEBVS; Usman Jaffer, BSc, MBBS, FRCS, MSc, PhD, PGCE, FHEA; Matt Bown, MD, FRCS; Zoran Rancic, MD, PhD; Dieter Mayer, MD; Jan Brunkwall, MD, PhD; Michael Gawenda, MD, PhD; Tilo Kölbel, MD, PhD; Elixène Jean-Baptiste, MD, PhD, FEBVS; Frans Moll, MD, PhD; Paul Berger, MD; Christos D. Liapis, MD, PhD; Konstantinos G. Moulakakis, MD, PhD, FEBVS; Marcus Langenskiöld, MD, PhD; Håkan Roos, MD; Thomas Larzon, MD, PhD; Artai Pirouzram, MD; Anders Wanhainen, MD, PhD; for the European MAA collaborators

Background: Mycotic aortic aneurysm (MAA) is a rare and life-threatening disease. The aim of this European multicenter collaboration was to study the durability of endovascular aortic repair (EVAR) of MAA, by assessing late infection–related complications and long-term survival.

02 diciembre 2014

CIRCULATION. Interventional Cardiology. Arrhythmia Burden in Elderly Patients With Severe Aortic Stenosis as Determined by Continuous Electrocardiographic Recording

Marina Urena, MD; Salim Hayek, MD; Asim N. Cheema, MD; Vicenç Serra, MD; Ignacio J. Amat-Santos, MD; Luis Nombela-Franco, MD; Henrique B. Ribeiro, MD; Ricardo Allende, MD; Jean-Michel Paradis, MD; Eric Dumont, MD; Vinod H. Thourani, MD; Vasilis Babaliaros, MD; Jaume Francisco Pascual, MD; Carlos Cortés, MD; Bruno García del Blanco, MD; François Philippon, MD; Stamatios Lerakis, MD; Josep Rodés-Cabau, MD

Background: This study sought to evaluate the prevalence of previously undiagnosed arrhythmias in candidates for transcatheter aortic valve replacement (TAVR) and to determine the impact on therapy changes and arrhythmic events after the procedure.

30 octubre 2014

CIRCULATION. Epidemiology and Prevention. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation

David J. Graham, MD, MPH; Marsha E. Reichman, PhD; Michael Wernecke, BA; Rongmei Zhang, PhD; Mary Ross Southworth, PharmD; Mark Levenson, PhD; Ting-Chang Sheu, MPH; Katrina Mott, MHS; Margie R. Goulding, PhD; Monika Houstoun, PharmD, MPH; Thomas E. MaCurdy, PhD; Chris Worrall, BS; Jeffrey A. Kelman, MD, MMSc

Background: The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established.

01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Extended Use of Percutaneous Edge-to-Edge Mitral Valve Repair Beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) Criteria. 30-Day and 12-Month Clinical and Echocardiographic Outcomes From the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) Registry

Guilherme F. Attizzani, MD∗; Yohei Ohno, MD∗; Davide Capodanno, MD, PhD∗; Stefano Cannata, MD∗; Fabio Dipasqua, MD∗; Sebastiano Immé, MD∗; Sarah Mangiafico, MD∗; Marco Barbanti, MD∗; Margherita Ministeri, MD∗; Anna Cageggi, MD∗; Anna Maria Pistritto, MD∗; Sandra Giaquinta, MD∗; Silvia Farruggio, MD∗; Marta Chiarandà, MD∗; Giuseppe Ronsivalle, MD∗; Audrey Schnell, PhD†; Salvatore Scandura, MD∗; Corrado Tamburino, MD, PhD∗; Piera Capranzano, MD, PhD∗; Carmelo Grasso, MD∗

Objectives: This study sought to compare, in high-risk patients with 3+ to 4+ mitral regurgitation (MR) dichotomized by baseline echocardiographic features, acute, 30-day, and 12-month outcomes following percutaneous mitral valve repair using the MitraClip.

01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Transfemoral Implantation of Transcatheter Heart Valves After Deterioration of Mitral Bioprosthesis or Previous Ring Annuloplasty

Claire Bouleti, MD, PhD∗; Amir-Ali Fassa, MD∗; Dominique Himbert, MD∗; Eric Brochet, MD∗; Gregory Ducrocq, MD∗; Mohammed Nejjari, MD∗; Walid Ghodbane, MD†; Jean-Pol Depoix, MD‡; Patrick Nataf, MD†; Alec Vahanian, MD∗

Objectives: This study sought to evaluate the feasibility of transfemoral transcatheter heart valve (THV) implantation in failed mitral bioprostheses and ring annuloplasties.